Efficacy of high- versus moderate-dose statin therapy on lower extremity artery disease after revascularization
Aim: Statins are one of the most important agents in the treatment of atherosclerotic peripheral arterial disease. We aim to compare high- and moderate-dose statin therapy in patients with lower extremity artery disease (LEAD) who have undergone percutaneous transluminal angioplasty (PTA). Patients and Methods: Ninety-four patients treated with PTA were selected consecutively and retrospectively and were divided into two groups according to the high- or moderate-dose statin treatments they were given. Groups were compared for the absence of restenosis and occlusion as primary patency and the need for reintervention in the treated arterial segment as secondary patency. All patients underwent computed tomography (CT) angiography or duplex scan one year after receiving PTA. Results: Coronary revascularization (p<0.001) and prior statin usage (p:0.02) were more common in the high-dose statin group when compared to the moderate-dose statin group. Lesion characteristics did not differ between the two groups. Primary patency rate was significantly higher (36.1% vs. 27.6%, p 0.01) in the high-dose statin group. Major amputation (4.2% vs. 10.6%, p:0.03) and minor amputation (12.7% vs. 19.1%, p:0.03) rates were significantly lower in the high-dose statin group. Regression analysis revealed that the usage of high-dose statin therapy was an independent predictor of higher primary patency in patients who were treated with prior PTA(Odds ratio:2.208, p<0.001) Conclusion: High-dose long-term statin treatment might have better outcomes on primary patency in patients who underwent prior PTA for infrapopliteal lesions as a subgroup of peripheral artery disease. The administration of the high-dose long-term statin therapy might be important in the prognosis of peripheral arterial disease, especially for those with infrapopliteal lesions.
___
- Istvan ES, Deisenhofer J. Structural mechanism for statin
inhibition of HMG-CoA reductase. Science 2001;292:1160-4.
doi: 10.1126/science.1059344.
- Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS
Guidelines for the Management of Dyslipidaemias. EurHeart J
2016; 37:2999. doi: 10.1093/eurheartj/ehw272.
- Mach F, Baigent C, Catapano AL, et al. ESC Scientific
Document Group. 2019 ESC/EAS Guidelines for the
management of dyslipidaemias: lipid modification to reduce
cardiovascular risk. Eur Heart J 2020 Jan 1; 41:111-88. doi:
10.1093/eurheartj/ehz455.
- Aung PP, Maxwell HG, Jepson RG, et al. Lipid-lowering
for peripheral arterial disease of the lower limb. Cochrane
Database Syst Rev 2007; 4; CD000123. doi:10.1002/14651858.
CD000123.pub2.
- Antoniou GA, Fisher RK, Georgiadis GS, et al. Statin therapy
in lower limb peripheral arterial disease: systematic review
and meta-analysis.Vascul Pharmacol 2014;63:79-87. doi:
10.1016/j.vph.2014.09.001.
- Heart Protection Study Collaborative Group. Randomized
trial of the effects of cholesterol-lowering with simvastatin
on peripheral vascular and other major vascular outcomes in
20,536 people with peripheral arterial disease and other highrisk
conditions. J Vasc Surg 2007; 45:645-54. doi: 10.1016/j.
jvs.2006.12.054.
- Kumbhani DJ, Steg PG, Cannon CP, et al. Statin therapy and
long-term adverse limb outcomes in patients with peripheral
artery disease: insights from the REACH registry. EurHeart J
2014; 35:2864-72. doi: 10.1093/eurheartj/ehu080.
- Rand T, Uberoi R. Current status of interventional radiology
treatment of infrapopliteal arterial disease. Cardiovasc Intervent
Radiol 2013; 36: 588-98. doi: 10.1007/s00270.012.0524-8.
- Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC
Guidelines on the Diagnosis and Treatment of Peripheral
Arterial Diseases, in collaboration with the European Society
for Vascular Surgery (ESVS). Rev Esp Cardiol (EnglEd) 2018 ;
71:111. doi: 10.1016/j.rec.2017.12.014.
- Aboyans V, Ricco JB, Bartelink MEL, et. Al. ESC Scientific
Document Group. 2017 ESC Guidelines on the Diagnosis and
Treatment of Peripheral Arterial Diseases, in collaboration with
the European Society for Vascular Surgery (ESVS): Document
covering atherosclerotic disease of extracranial carotid and
- vertebral, mesenteric, renal, upper and lower extremity
arteriesEndorsed by: the European Stroke Organization (ESO)
The Task Force for the Diagnosis and Treatment of Peripheral
Arterial Diseases of the European Society of Cardiology (ESC)
and of the European Society for Vascular Surgery (ESVS). Eur
Heart J 2018 ; 39:763-816. doi: 10.1093/eurheartj/ehx095.
- Elsayed S, Clavijo LC. Critical limb ischemia. Cardiol Clin
2015; 33:37-47. doi: 10.1016/j.ccl.2014.09.008.
- Fowkes FG, Housley E, Riemersma RA, et al. Smoking, lipids,
glucose intolerance, and blood pressure as risk factors for
peripheral atherosclerosis compared with ischemic heart
disease in the Edinburgh Artery Study. Am J Epidemiol 1992;
135:331-40. doi: 10.1093/oxfordjournals.aje.a116294
- Schmidt A, Ulrich M, Winkler B, et al. Angiographic patency
and clinical outcome after balloon‑angioplasty for extensive
infrapopliteal arterial disease. Catheter Cardiovasc Interv
2010;76:1047-54. doi: 10.1002/ccd.22658.
- Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis
of cardiovascular outcomes trials comparing intensive versus
moderate statin therapy. J Am Coll Cardiol 2006;48:438-45.
doi: 10.1016/j.jacc.2006.04.070.
- Pedersen TR, Faergeman O, Kastelein JJ, et al. Highdose
atorvastatin vs usual-dose simvastatin for secondary
prevention after myocardial infarction: the IDEAL study: a
randomized controlled trial. JAMA 2005;294:2437-45. doi:
10.1001/jama.294.19.2437.
- Arya S, Khakharia A, Binney ZO, et al. Association of statin
dose with amputation and survival in patients with peripheral
artery disease. Circulation 2018;137:1435-46. doi: 10.1161/
CIRCULATIONAHA.117.032361.
- Foley TR, Singh GD, Kokkinidis DG, et al. High-intensity
statin therapy is associated with improved survival in patients
with peripheral artery disease. J Am Heart Assoc 2017
;6:e005699. doi: 10.1161/JAHA.117.005699.
- Stoekenbroek RM, Boekholdt SM, Fayyad R, et al. Incremental
decrease in end points through aggressive lipid lowering study
group. High-dose atorvastatin is superior to moderate-dose
simvastatin in preventing peripheral arterial disease. Heart
2015;101:356-62. doi: 10.1136/heartjnl-2014-306906.
- Spring S, Simon R, van der Loo B, et al. High-dose atorvastatin
in peripheral arterial disease (PAD): effect on endothelial
function, intima-media-thickness and local progression of
PAD. An open randomized controlled pilot trial. Thromb
Haemost 2008 ;99:182-9.
- Fowkes FG, Rudan D, Rudan I, et al. Comparison of global
estimates of prevalence and risk factors for peripheral artery
disease in 2000 and 2010: a systematic review and analysis.
Lancet 2013;382:1329-40. doi: 10.1160/TH07-04-0265.
- Romiti M, Albers M, Brochado-Neto FC, et al. Meta-analysis
of infrapopliteal angioplasty for chronic critical limb ischemia.
J Vasc Surg 2008:47:975-81. doi: 10.1016/j.jvs.2008.01.005.
- Fernandez N, McEnaney R, Marone LK, et al. Predictors
of failure and success of tibial interventions for critical
limb ischemia. J Vasc Surg 2010 ;52:834-42. doi: 10.1016/j.
jvs.2010.04.070.
- Sadowitz B, Maier KG, Gahtan V. Basic science review:
Statin therapy—Part I: The pleiotropic effects of statins in
cardiovascular disease. Vasc Endovascular Surg 2010 ;44:241-
51. doi: 10.1177/153.857.4410362922. .
- Silva VS, Martin LC, Franco RJ, et al. Pleiotropic effects of
statins may improve outcomes in atherosclerotic renovascular
disease. Am J Hypertens2008 ;21:1163-8. doi: 10.1038/
ajh.2008.249.
- Subramanian S, Emami H, Vucic E, et al. High-dose
atorvastatin reduces periodontal inflammation: a novel
pleiotropic effect of statins. J Am Coll Cardiol 2013 ;62:2382-
91. doi: 10.1016/j.jacc.2013.08.1627.